PTGES3

PTGES3 (cPGES/p23) is an Hsp90-associated co-chaperone that operates at the intersection of steroid receptor signaling, prostaglandin metabolism, and inflammatory pathways (PMID:17438133, PMID:17719010). As a stabilizer of the Hsp90 chaperone complex, it is required for glucocorticoid receptor function in vivo: PTGES3-knockout mice fail to induce GR-sensitive gluconeogenic enzymes prenatally and phenocopy GR-deficient neonates, with retarded lung development (PMID:17438133). In prostate cancer cells PTGES3 binds the androgen receptor directly, forms a nuclear AR complex, and is required for AR protein stability and transcription at AR target genes; its loss collapses AR protein levels and triggers cell-cycle arrest and death in AR-driven models (PMID:41193657). PTGES3 also contributes to prostaglandin homeostasis, with knockout pups showing reduced lung PGE2 content (PMID:17719010) and PTGES3 positively regulating the PGE2-inactivating enzyme 15-PGDH (PMID:21334450), although metabolite profiling in embryonic tissues and fibroblasts argued against a general role in PGE2 biosynthesis (PMID:17438133). Covalent modification of Cys58 at an allosteric site disrupts the PTGES3-Hsp90 complex and inhibits its PGE2 synthase activity, suppressing NF-κB signaling (PMID:42144059). Across multiple cancer contexts—breast, hepatocellular, and prostate—PTGES3 depletion impairs proliferation, migration, and viability, marking it as a candidate dependency amenable to degrader approaches (PMID:41193657, PMID:38245717, PMID:39726032).

1. 2007 High

   Establishing whether PTGES3 has an essential physiological function clarified its role as a stabilizer of the glucocorticoid receptor complex rather than solely a prostaglandin synthase.

   Evidence Knockout mouse with GR-sensitive gluconeogenic enzyme induction analysis and arachidonic acid metabolite profiling

   PMID:17438133

   Open questions at the time

   • Did not resolve the direct biochemical mechanism of GR complex stabilization
   • Metabolite data conflicted with a PGE2 biosynthesis role
2. 2007 Medium

   The same knockout revealed a proliferation requirement, indicating PTGES3 function extends beyond GR stabilization.

   Evidence Body weight measurements and primary fibroblast proliferation assays in null mice

   PMID:17438133

   Open questions at the time

   • Molecular driver of the proliferation defect not identified
   • Single lab
3. 2007 Medium

   An independent knockout addressed the contested PGE2 question, providing evidence that PTGES3 contributes to lung PGE2 in vivo.

   Evidence Knockout targeting catalytic Tyr9 exons with lung PGE2 quantification

   PMID:17719010

   Open questions at the time

   • Partially contradicts the metabolite findings of the parallel knockout study
   • Tissue-specific basis of the discrepancy unresolved
4. 2011 Medium

   Linking PTGES3 to 15-PGDH expression extended its influence over prostaglandin homeostasis to PGE2 degradation, not just synthesis.

   Evidence Null fibroblast analysis, siRNA knockdown, and overexpression with 15-PGDH promoter luciferase reporter

   PMID:21334450

   Open questions at the time

   • Direct vs indirect transcriptional mechanism not established
   • Single lab; rat 3Y1 cell context
5. 2024 Medium

   Loss-of-function in breast cancer cells positioned PTGES3 as a tumor cell growth and motility factor.

   Evidence siRNA knockdown with CCK-8 viability and wound-healing migration assays

   PMID:38245717

   Open questions at the time

   • Molecular pathway mediating proliferation/migration not defined
   • Single lab
6. 2024 Medium

   A peptide-PROTAC demonstrated PTGES3 is druggable by targeted degradation and that its depletion suppresses HCC malignancy.

   Evidence Liposomal peptide-PROTAC with proteasomal degradation assays and HCC xenograft models

   PMID:39726032

   Open questions at the time

   • Specificity of the binding peptide for PTGES3 not fully delineated
   • Downstream effector pathway in HCC not identified
7. 2025 High

   An unbiased screen identified PTGES3 as a direct AR-binding regulator of AR stability, defining a chaperone role specific to prostate cancer dependency.

   Evidence Genome-scale CRISPRi screen with live-cell AR reporter, direct binding/co-IP, AR stability assays, and chromatin AR target gene analysis

   PMID:41193657

   Open questions at the time

   • Structural basis of the direct PTGES3-AR interaction not resolved
   • Whether AR regulation requires Hsp90 co-chaperone activity not tested
8. 2026 High

   Covalent targeting of Cys58 mapped an allosteric site whose modification couples PTGES3 enzymatic and chaperone functions to NF-κB suppression.

   Evidence Activity-based protein profiling, Cys58 mutagenesis, PGE2 synthase assay, and Ptges3 knockdown in bleomycin/LPS mouse models

   PMID:42144059

   Open questions at the time

   • How Cys58 modification mechanistically disrupts Hsp90 binding not structurally defined
   • Link between PGE2 synthase activity loss and NF-κB suppression not dissected

• It remains unresolved how PTGES3's distinct activities—Hsp90 co-chaperone, steroid receptor stabilizer, and PGE2 synthase—are mechanistically integrated within a single protein and which is operative in each disease context.
• No unified structural model linking the catalytic, Hsp90-binding, and AR-binding functions
• Context-dependence of PGE2 synthase activity in vivo unresolved